Data is not available for this company.
No data found
No data found
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
No data to display
Return on Equity has declined versus last 3 years average to %
Sales growth has been subdued in last 3 years %
Sales growth is not so good in last 4 quarters at %
Standalone | Consolidated | |
---|---|---|
TTM EPS (₹) | 0 | - |
TTM Sales (₹ Cr.) | 322 | - |
BVPS (₹.) ⓘ | 0 | - |
Reserves (₹ Cr.) ⓘ | 78 | - |
P/BV ⓘ | 0.00 | - |
PE ⓘ | 0.00 | - |
From the Market | |
---|---|
52 Week Low / High (₹) | - / - |
All Time Low / High (₹) | - / - |
Market Cap (₹ Cr.) | 0 |
Equity (₹ Cr.) | 0 |
Face Value (₹) | 10 |
Industry PE ⓘ | 20 |
Calyx Chemicals and Pharmaceuticals Limited was originally incorporated as Shree Deep Jyote Industrial Paints Private Limited on January 14, 1986 .The company’s name was changed to Calyx Chemicals and Pharmaceuticals Private Limited. The company was converted into a public limited company and consequently the name of the company was changed to Calyx Chemicals and Pharmaceuticals Limited.
The company was originally promoted by Dharmesh Shah and Satyen Shah inter alia to manufacture, produce, refine, recover, extract, distil, concentrate, dilute, rectify, convert, buy, sell, export, import or otherwise deal in all types of paints, synthetic paints and thinners, colored or other cements, varnishes, synthetic resins, enamel, lacquers, distempers, disinfectants, oils, wood preservative, fruit or vegetable or other preservatives, printing and making inks, dry inks, writing inks, polishes of description including metal, wood, paper, polishes, crayons, powders, electroplating, abrasive and its chemicals, shoe dressing, greases, Vaselines, creams, glue, gelatine and other glue preparations and allied products, methylated and rectified spirits, dry or other colours, water dyes, die intermediates, pigments dyes, all type of turpentine including Canada turpentine from fine larchfir, nstalmen and other trees.
The Promoter-Directors, Smitesh Chandravadan Shah and Bharat Sukhlal Mehta along with Indulal Dalichand Doshi acquired this company in the year 1995. Subsequently, the business objects were changed to include the manufacture and sale of pharmaceutical products and the company’s name was changed to Calyx Chemicals and Pharmaceuticals Private Limited accordingly. In the year 2004, the company acquired the properties and assets of Indi Systems. In the year 2006, Calyx Pharmaceuticals and Chemicals Private Limited (a company promoted by Smitesh Chandravadan Shah, Bharat Sukhlal Mehta and Indulal Dalichand Doshi) merged with Calyx Chemicals and Pharmaceuticals Private Limited. Pursuant thereto and upon conversion into a public limited company, the company is presently named Calyx Chemicals and Pharmaceuticals Limited.
Smitesh Chandravadan Shah, Chairman and Managing Director, is a commerce graduate and has been closely associated with the pharmaceutical industry for over 30 years. He is currently the Chairman of The Pharmaceutical Export Promotion Council of India (Pharmexcil) and in the past, has held prestigious positions such as Honorary General Secretary of Indian Drugs Manufacturers Association (IDMA) and Senior Vice President of the Bulk Drugs Manufacturers Association (BDMA). Dr. Bansi Lal, President and Head of Department, R & D, has more than 35 years of experience in new drug discovery, has published 56 papers (national and international journals) and has 56 patents to his credit in India and abroad.
Business Overview:
The company is a manufacturer of Active Pharmaceutical Ingredients and Intermediates in India with strong presence in the manufacture of macrolides, anti- tuberculosis and anti-depressants and increasing focus on CRAMS to transnational pharmaceutical companies. The company has, over the years, moved from a single product (Anti TB - Pyrazinamide) to a multi-product portfolio comprising Anti-TB, Macrolides, Anti-Depressants, Anti-Hypertensives and Anti-Malarial (the products business).The company has also spent a substantial part of its efforts in the last 5-6 years in creating a strong base for theCRAMS business:
These developments have enabled the company to make inroads into the high growth, high margin CRAMS business apart from its established Products business. The company is managed by a team of experienced and professional personnel with exposure in various aspects of pharmaceutical industry including production, research and development, marketing and finance.
The Business segments:
The business of the company broadly comprises of the following segments:
Group Companies:
Private companies
Limited liability partnership firms
Partnership firms
Sole proprietorships
HUFs
Major Events: